Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du Sells 7,072 Shares

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 7,072 shares of the business's stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $35.23, for a total transaction of $249,146.56. Following the completion of the sale, the chief executive officer directly owned 536,962 shares of the company's stock, valued at approximately $18,917,171.26. This trade represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Ying Du also recently made the following trade(s):

• On Monday, June 30th, Ying Du sold 6,918 shares of Zai Lab stock. The stock was sold at an average price of $35.52, for a total transaction of $245,727.36.
• On Thursday, June 26th, Ying Du sold 23,669 shares of Zai Lab stock. The shares were sold at an average price of $36.13, for a total value of $855,160.97.
• On Tuesday, May 13th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $28.57, for a total value of $1,428,500.00.
• On Wednesday, May 14th, Ying Du sold 46,389 shares of Zai Lab stock. The stock was sold at an average price of $28.09, for a total transaction of $1,303,067.01.
• On Friday, April 4th, Ying Du sold 2,945 shares of Zai Lab stock. The stock was sold at an average price of $33.11, for a total transaction of $97,508.95.

Zai Lab Trading Up 2.6%

ZLAB traded up $0.94 during trading on Friday, hitting $36.43. The company's stock had a trading volume of 581,960 shares, compared to its average volume of 914,335. The firm has a market capitalization of $4.05 billion, a price-to-earnings ratio of -14.63 and a beta of 0.99. Zai Lab Limited Unsponsored ADR has a twelve month low of $16.01 and a twelve month high of $44.34. The business's fifty day simple moving average is $33.80 and its 200 day simple moving average is $31.42.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.05. The company had revenue of $106.49 million during the quarter, compared to analyst estimates of $118.40 million. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. As a group, equities research analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on ZLAB shares. Leerink Partners set a $75.00 price target on Zai Lab and gave the company an "outperform" rating in a research note on Monday, June 30th. JPMorgan Chase & Co. increased their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a research report on Thursday, March 13th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a research note on Thursday, March 27th. Finally, Wall Street Zen lowered shares of Zai Lab from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $54.28.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. US Bancorp DE raised its holdings in shares of Zai Lab by 1,671.9% during the 4th quarter. US Bancorp DE now owns 5,865 shares of the company's stock worth $154,000 after acquiring an additional 5,534 shares during the period. Raymond James Financial Inc. acquired a new stake in Zai Lab during the fourth quarter worth about $1,032,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Zai Lab during the fourth quarter worth about $1,674,000. Daiwa Securities Group Inc. boosted its holdings in Zai Lab by 44.7% in the 4th quarter. Daiwa Securities Group Inc. now owns 13,833 shares of the company's stock valued at $362,000 after purchasing an additional 4,276 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Zai Lab by 39.3% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 841,735 shares of the company's stock valued at $22,045,000 after buying an additional 237,582 shares during the period. 41.65% of the stock is owned by hedge funds and other institutional investors.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.